TrialAnnals of oncology : official journal of the European Society for Medical Oncology2024

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

N M Tannir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.